Inventor · disambiguated record
Ety Klinger
Also filed as: KLINGER ETY
11 granted patents·18 pending applications·196 citations·filing 2002–2019
93Inventor score
Top patents by PatentIndex Score
29 records- 0197US9155776B2Low frequency glatiramer acetate therapyYEDA RES & DEV·Filed 2015·Granted Oct 13, 2015·12 cites·30 claims
- 0296US9402874B2Low frequency glatiramer acetate therapyYEDA RES & DEV·Filed 2015·Granted Aug 2, 2016·10 cites·28 claims
- 0396US8969302B2Low frequency glatiramer acetate therapyKLINGER ETY·Filed 2013·Granted Mar 3, 2015·19 cites·12 claims
- 0496US8399413B2Low frequency glatiramer acetate therapyKLINGER ETY·Filed 2010·Granted Mar 19, 2013·24 cites·20 claims
- 0596US8232250B2Low frequency glatiramer acetate therapyKLINGER ETY·Filed 2011·Granted Jul 31, 2012·26 cites·20 claims
- 0695US7923215B2Process for the measurement of the potency of glatiramer acetateTEVA PHARMA·Filed 2008·Granted Apr 12, 2011·32 cites·30 claims
- 0793US7429374B2Process for the measurement of the potency of glatiramer acetateTEVA PHARMA·Filed 2002·Granted Sep 30, 2008·41 cites·9 claims
- 0892US8389228B2Process for the measurement of the potency of glatiramer acetateKLINGER ETY·Filed 2011·Granted Mar 5, 2013·18 cites·13 claims
- 0978US8759314B2Methods for treating multiple sclerosis using antisense oligonucleotidesKLINGER ETY·Filed 2013·Granted Jun 24, 2014·6 cites·31 claims
- 1077US2019175494A1Low frequency glatiramer acetate therapyYeda res & development co ltd·Filed 2019·Application pending·0 cites
- 1175US2019054013A1Low frequency glatiramer acetate therapyYeda res & development co ltd·Filed 2018·Application pending·0 cites
- 1274US2018311149A1Low frequency glatiramer acetate therapyYeda res & development co ltd·Filed 2018·Application pending·0 cites
- 1373US8415314B2Methods for treating multiple sclerosis using antisense oligonucleotidesKLINGER ETY·Filed 2009·Granted Apr 9, 2013·2 cites·33 claims
- 1472US2017296464A1Low frequency glatiramer acetate therapyYEDA RES & DEV·Filed 2017·Application pending·0 cites
- 1572US2018064639A1Low frequency glatiramer acetate therapyYeda res & development co ltd·Filed 2017·Application pending·0 cites
- 1671US2017196803A1Low frequency glatiramer acetate therapyYEDA RES & DEV·Filed 2017·Application pending·0 cites
- 1770US2017095523A1Low frequency glatiramer acetate therapyYEDA RES & DEV·Filed 2016·Application pending·0 cites
- 1869US2016250251A1Low frequency glatiramer acetate therapyYEDA RES & DEV·Filed 2016·Application pending·0 cites
- 1969US2018185274A1Low frequency glatiramer acetate therapyYeda res & development co ltd·Filed 2018·Application pending·0 cites
- 2067US7294687B2Parenteral formulations of a peptide for the treatment of systemic lupus erythematosusTEVA PHARMA·Filed 2004·Granted Nov 13, 2007·6 cites·25 claims
- 2166US2015164977A1Low frequency glatiramer acetate therapyYEDA RES & DEV·Filed 2015·Application pending·0 cites
- 2264US2015094488A1Process for the measurement of the potency of glatiramer acetateKLINGER ETY·Filed 2014·Application pending·0 cites
- 2360US2012309671A1Process for the measurement of the potency of glatiramer acetateKLINGER ETY·Filed 2012·Application pending·0 cites
- 2460US2008287366A1Parenteral formulations of a peptide for the treatment of systemic lupus erythematosusTEVA PHARMA·Filed 2007·Application pending·0 cites
- 2556US2009169559A1Parenteral formulations of peptides for the treatment of systemic lupus erythematosusTEVA PHARMA·Filed 2008·Application pending·0 cites
- 2656US2016025707A1Process for the measurement of the potency of glatiramer acetateKLINGER ETY·Filed 2015·Application pending·0 cites
- 2746US2013023485A1Parenteral formulations of peptides for the treatment of systematic lupus erythematosusTEVA PHARMA·Filed 2012·Application pending·0 cites
- 2845US2005008634A1Parenteral formulations of peptides for the treatment of systemic lupus erythematosusFiled 2004·Application pending·0 cites
- 2932US2007244056A1Combination Therapy With Glatiramer Acetate and RiluzoleHAYARDENY LIAT·Filed 2005·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →